Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Paul Mahoney

Interventional Cardiology Greenville, NC Medical Doctor

NPI 1578539201 CMS profile 343452

115 Heart Dr, Greenville, NC 27834

Open in the dashboard

General payments

$1,692,202

2,211 records reported · program years 2019–2025

Research payments

$24,094

Paid to them · 52 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,252,488 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Paul Mahoney of Greenville, NC is reported in the CMS Open Payments database as having received $1,692,202 across 2,211 general payments and $24,094 in research payments paid to them. Separately, studies naming them as principal investigator received $2,252,488 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $42,508 138
2024 General $213,666 276
2023 General $484,655 483
2023 Research $1,969 8
2022 General $307,031 408
2022 Research $8,438 21
2021 General $217,924 292
2021 Research $9,000 14
2020 General $150,829 210
2020 Research $4,688 9
2019 General $275,590 404

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paul Mahoney
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Paul Mahoney were reported at $42,508. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Paul Mahoney Interventional Cardiology median Middle half National median
2019 $275,590 $1,097 $329–$3,048 $163
2020 $150,829 $473 $161–$1,480 $114
2021 $217,924 $677 $233–$1,827 $132
2022 $307,031 $978 $333–$2,724 $149
2023 $484,655 $1,136 $382–$2,986 $160
2024 $213,666 $1,181 $395–$3,326 $164
2025 $42,508 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Edwards Lifesciences Corporation $521,363 716 payments
  2. Medtronic, Inc. $436,904 507 payments
  3. Medtronic Vascular, Inc. $243,047 226 payments
  4. Abbott Laboratories $225,263 405 payments
  5. Boston Scientific Corporation $191,064 256 payments
  6. Abiomed $55,755 47 payments
  7. Baylis Medical Company Inc $9,072 11 payments
  8. Teleflex LLC $4,435 11 payments
  9. Integer Holdings Corporation $2,820 1 payment
  10. Inari Medical, Inc. $571 2 payments
  11. Other $1,907 29 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $688,874 246 payments
  2. Consulting Fee $502,485 135 payments
  3. Travel and Lodging $349,479 629 payments
  4. Food and Beverage $68,783 1,171 payments
  5. Honoraria $63,306 19 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $16,775 7 payments
  7. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $1,700 2 payments
  8. Grant $650 1 payment
  9. Education $149 1 payment
Products named General payments · program years 2019–2025
  1. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $353,939 290 payments
  2. COREVALVE EVOLUT R $299,987 338 payments
  3. CoreValve Evolut Transcatheter Valve Systems $241,566 221 payments
  4. CoreValve Evolut Transcatheter Valve Systems $109,039 84 payments
  5. Edwards SAPIEN 3 Transcatheter Heart Valve $72,666 167 payments
  6. MITRACLIP Vascular $57,856 57 payments
  7. Impella $55,422 40 payments
  8. WATCHMAN Access System $53,924 70 payments
  9. MITRACLIP Structural Heart $44,255 65 payments
  10. NAVITOR $43,943 52 payments
  11. Other $235,350 599 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic, Inc. $19,406 43 payments
  2. Medtronic Vascular, Inc. $4,688 9 payments

Billing to Medicare

Part B · data year 2024 · 54 billing codes

Paid by Medicare

$78,714

Medicare's payments for the services billed

Medicare patients

205

Average age 77

Services billed

568

83 women, 122 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Heart failure 74%
Arthritis 64%
Atrial fibrillation 57%
Diabetes 56%
Chronic kidney disease 56%
COPD 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREPROSTINIL
$27 — —
XARELTO
$13 — —
CLEVIPREX
$9 — —
KENGREAL
$9 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

2,263 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record